Experimental Glioblastoma Vaccine Shows Promise in Slowing Brain Tumor Growth
In phase 2 clinical trials, 97% of patients receiving a new glioblastoma treatment did not experience tumor progression in the six months following treatment. Learn more about the immunotherapy under development.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
“Despite improvements in surgery, medical therapies and radiation, outcomes from treatment of glioblastoma still remain dismal,” says neuro-oncologist Manmeet Ahluwalia, MD, Director of the Brain Metastasis Research Program at Cleveland Clinic.
Dr. Ahluwalia is helping lead a clinical trial of a new glioblastoma treatment called SurVaxM. It’s an immunotherapy for brain cancer that works by stimulating a person’s own body to kill tumor cells that contain survivin, a protein that helps those cancer cells resist traditional treatments.
Positive results in first trials
So far, the results are encouraging. Nearly 97% of the 63 patients in the phase 2 clinical trial did not experience tumor progression in the six months following treatment with the vaccine after surgery, chemotherapy and radiation.